Author

Raffaele Marfella

Professore Ordinario Medicina Interna Universit

Biography

Dr. Raffaele Marfella  is an Associate professor in the Department of Medical Sciences, Surgical, Neurological, Metabolic and Aging Science, Second University of Naples, Italy. His study interests major on Department of Medical Sciences. Currently , Dr. Raffaele Marfella is the author/editors/reviewer in several international journals. He published 10 articles in many journals and the articles are informative and got good citations
Title
Cited by
Year
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international …
P Paolisso, L Bergamaschi, G Santulli, E Gallinoro, A Cesaro, F Gragnano, ...Cardiovascular Diabetology 21 (1), 1-12, 2022202
64
2022
Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes
R Marfella, C Sardu, N D’Onofrio, F Prattichizzo, L Scisciola, V Messina, ...Nature communications 13 (1), 2318, 2022202
27
2022
Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
L Scisciola, V Cataldo, F Taktaz, RA Fontanella, A Pesapane, P Ghosh, ...Frontiers in Cardiovascular Medicine 9, 1008922, 222
20
2022
SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study
C Sardu, MM Massetti, P Rambaldi, G Gatta, S Cappabianca, FC Sasso, ...Metabolism 137, 155243, 2022202
18
2022
Exosomal miR-145 and miR-885 regulate thrombosis in COVID-19
J Gambardella, U Kansakar, C Sardu, V Messina, SS Jankauskas, ...Journal of Pharmacology and Experimental Therapeutics 384 (1), 109-115, 2023202
17
2023
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
A Cesaro, F Gragnano, P Paolisso, L Bergamaschi, E Gallinoro, C Sardu, ...Frontiers in Cardiovascular Medicine 9, 1012220, 2022202
16
2022
Coronary microvascular dysfunction in diabetes mellitus: pathogenetic mechanisms and potential therapeutic options
T Salvatore, R Galiero, A Caturano, E Vetrano, G Loffredo, L Rinaldi, ...Biomedicines 10 (9), 2274, 2022202
12
2022
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc …
FC Sasso, V Simeon, R Galiero, A Caturano, L De Nicola, P Chiodini, ...Cardiovascular Diabetology 21 (1), 1-10, 2022202
12
2022
Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes
R Marfella, L Scisciola, N D’Onofrio, C Maiello, MC Trotta, C Sardu, ...Pharmacological Research 184, 106448, 2022202
11
2022
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry
P Paolisso, L Bergamaschi, F Gragnano, E Gallinoro, A Cesaro, C Sardu, ...Pharmacological research 187, 106597, 2023202
11
2023
Non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and non-viral hepatocarcinoma: Pathophysiological mechanisms and new therapeutic strategies
E Vetrano, L Rinaldi, A Mormone, C Giorgione, R Galiero, A Caturano, ...Biomedicines 11 (2), 468, 2023202
10
2023
GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives
R Nevola, R Epifani, S Imbriani, G Tortorella, C Aprea, R Galiero, ...International Journal of Molecular Sciences 24 (2), 1703, 2023202
9
2023
Angiotensin receptor/Neprilysin inhibitor effects in CRTd non-responders: From epigenetic to clinical beside
C Sardu, M Massetti, L Scisciola, MC Trotta, M Santamaria, M Volpicelli, ...Pharmacological Research 12, 106303, 2022202
8
2022
COVID-19 causes ferroptosis and oxidative stress in human endothelial cells
SS Jankauskas, U Kansakar, C Sardu, F Varzideh, R Avvisato, X Wang, ...Antioxidants 12 (2), 32, 2023202
6
2023
Effects of a combination of empagliflozin plus metformin vs. metformin monotherapy on NAFLD progression in type 2 diabetes: the IMAGIN pilot study
A Caturano, R Galiero, G Loffredo, E Vetrano, G Medicamento, C Acierno, ...Biomedicines 11 (2), 322, 2023202
5
2023
Glycated ACE2 reduces anti-remodeling effects of renin-angiotensin system inhibition in human diabetic hearts
R Marfella, N D’Onofrio, G Mansueto, V Grimaldi, MC Trotta, C Sardu, ...Cardiovascular Diabetology 21 (1), 1-14, 2022202
5
2022
Milk exosomal miR-27b worsen endoplasmic reticulum stress mediated colorectal cancer cell death
E Martino, A Balestrieri, L Mele, C Sardu, R Marfella, N D’Onofrio, ...Nutrients 1 (23), 5081, 2022202
4
2022
Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis
G Fuschillo, V Celentano, M Rottoli, G Sciaudone, AG Gravina, ...Digestive and Liver Disease, 2022202
4
2022
Association between renal function at admission and covid-19 in-hospital mortality in southern Italy: Findings from the prospective multicenter Italian covoca study
R Galiero, V Simeon, G Loffredo, A Caturano, L Rinaldi, E Vetrano, ...Journal of Clinical Medicine 11 (20), 6121, 2022202
3
2022
Peripheral neuropathy in diabetes mellitus: Pathogenetic mechanisms and diagnostic options
R Galiero, A Caturano, E Vetrano, D Beccia, C Brin, M Alfano, J Di Salvo, ...International Journal of Molecular Sciences 24 (4), 554, 20220
3
2023

Referred From: https://scholar.google.it/citations?user=lvTnnWsAAAAJ&hl=it

Cited by
Citations 29417
h-index 78
i10-index 223
Recommended Journals
Open Access Journals